Browse > Article

Long-Term Expression of von Willebrand Factor by a VSV-G Pseudotyped Lentivirus Enhances the Functional Activity of Secreted B-Domain-deleted Coagulation Factor VIII  

Park, Sang Won (School of Life Sciences and Biotechnology, Korea University)
Choi, Sang-Yun (School of Life Sciences and Biotechnology, Korea University)
Abstract
von Willebrand factor (vWF) is a multimeric glycoprotein which functions within the coagulation system. It colocalizes with factor VIII (FVIII) by non-covalent interaction and alters its intracellular trafficking. vWF is also instrumental in maintaining the stability of secreted FVIII. The principal objective of this study was to generate a lentivirus-based vWF expression vector for gene therapy of hemophilia A. We inserted a vWF of 8.8 Kb into a lentiviral vector thereby producing VSV-G-pseudotyped vEx52. However, its titer was quite low, presumably because the length of vWF gene exceeds the size limit of the lentiviral vector. In order to overcome the low-titer, we concentrated the vEx52 and thus increased the efficiency of transduction approximately 6-fold with $1/100^{th}$ of the volume. However, as concentration requires an additional laborious step, we attempted to enhance the transduction efficiency by deleting exons 24-46 and 29-46 in pRex52 to construct pRex23 and pRex28, and in pvEx52, yielding pvEx23 and pvEx28, respectively. The transfected pRex52 had a profound effect on the activity of secreted FVIII, and this activity declined as domains of vWF were deleted. However, when the domain-deleted vWF-lentiviruses were transduced into K562 cells, the vEx28 increased the activity of the secreted FVIII compared to what was observed with vEx52. This result is probably due to higher efficiencies of transduction and expression while retaining the essential domains required for proper interaction with FVIII.
Keywords
Coagulation Factor VIII; Gene Therapy; Lentivirus; von Willebrand Factor;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 1  (Related Records In Web of Science)
연도 인용수 순위
1 Doering, C., Parker, E. T., Healey, J. F., Craddock, H. N., Barrow, R. T., et al. (2002) Expression and characterization of recombinant murine factor VIII. Thromb. Haemost. 88, 450-458   DOI
2 Federici, A. B. (2003) The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 88, EREP02
3 Kaufman, R. J., Wasley, L. C., and Dorner, A. J. (1988) Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 263, 6352-6362
4 Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R. et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-269   DOI
5 Powell, J. S., Ragni, M. V., White, G. C. Lusher, J. M., Hillman- Wiseman, C., et al. (2003) Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 102, 2038-2045   DOI   ScienceOn
6 Kaufman, R. J., Pipe, S. W., Tagliavacca, L., Swaroop, M., and Moussalli, M. (1997) Biosynthesis, assembly and secretion of coagulation factor VIII. Blood 8, S3-14
7 Sadler, J. E. and Davie, E. W. (1994) In the molecular basis of blood disease, Stamatoyannopoulos, G., Nienhuis, A. W., Majerus, P. W., and Varmus, H. (eds.), pp. 657-700, Philadelphia, WB Saunders
8 Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., et al. (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185   DOI   ScienceOn
9 Tuddenham, E. G., Lane, R. S., Rotblat, F., Johnson, A. J., Snape, T. J., et al. (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br. J. Haematol. 52, 259-267   DOI   ScienceOn
10 Chang, L. J. and He, J. (2001) Retroviral vectors for gene therapy of AIDS and cancer. Curr. Opin. Mol. Ther. 3. 468-475
11 Rosenberg, J. B., Foster, P. A., Kaufman, R. J., Vokac, E. A., Moussalli, M., et al. (1998) Intracellular trafficking of Factor VIII to von Willebrand factor storage granules. J. Clin. Invest. 101, 613-624   DOI   ScienceOn
12 Eum, W. S., Jang, S. H., Kim, D. W., Choi, H. S., Choi, S. H., et al. (2005) Enhanced transduction of Cu, Zn-superoxide dismutase with HIV-1 Tat protein transduction domains at both termini. Mol. Cells 19, 191-197
13 Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., et al. (1999) Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 12, 10010-10018
14 De Meyer, D. F., Vanhoorelbeke, K., Chuah, M. K., Pareyn, I., Gillijns, V., et al. (2006) Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 107, 4728-4736   DOI   ScienceOn
15 Lewis, P., Hensel, M., and Emerman, M. (1992) Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11, 3053-3058
16 Burns, J., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.-K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037
17 Parolin, C., Taddeo, B., Palu, G., and Sodroski, J. (1996) Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 222, 415-422   DOI   ScienceOn
18 Park, S. W. and Choi, S. Y. (2004) A stable gene transfer system for hematopoietic progenitor cells from human bone marrow using pseudotyped retroviral vectors. Mol. Cells 17, 297-303
19 Yee, J., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J., et al. (1994) A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91, 9564-9568
20 Kohn, D. (2001) Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern. Med. 249, 379-390   DOI   ScienceOn
21 Over, J., Sixma, J. J., Bruine, M. H., Trieschnigg, M. C., Vlooswijk, R. A., et al. (1978) Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J. Clin. Invest. 62, 223-234
22 Gangadharan, B., Parker, E. T., Ide, L. M., Spencer, H. T., and Doering, C. B. (2006) High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 107, 3859-3864   DOI   ScienceOn
23 Sadler, J. E. (1998) Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67, 395-424   DOI   ScienceOn
24 Fay, P. J., Coumans, J. V., and Walker, F. J. (1991) von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J. Biol. Chem. 266, 2172-2177
25 Keeney, S. and Cumming, A. M. (2001) The molecular biology of von Willebrand disease. Clin. Lab. Haematol. 23, 209-230   DOI   ScienceOn
26 Chuah, M. K., Collen, D., and VandenDriessche, T. (2004) Clinical gene transfer studies for hemophilia A. Semin. Thromb. Hemost. 30, 249-256